Michael Bigham - Dec 12, 2022 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role
Exec. Chairman of the Board, Director
Signature
/s/ William M. Haskell, Attorney-in-Fact for Michael Bigham
Stock symbol
PRTK
Transactions as of
Dec 12, 2022
Transactions value $
-$101,085
Form type
4
Date filed
12/14/2022, 07:00 PM
Previous filing
Nov 23, 2022
Next filing
Dec 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Sale -$38.6K -19.5K -1.58% $1.98 1.21M Dec 12, 2022 Direct F1, F2
transaction PRTK Common Stock Sale -$62.5K -31.9K -2.63% $1.96 1.18M Dec 13, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit awards, pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.96 to $2.00. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.93 to $2.01. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.